Natco Pharma today said its marketing partner Alvogen has received final approval to market oseltamivir phosphate powder used for the treatment of influenza in the US.
"Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder for oral suspension in the United States," Natco Pharma said in a regulatory filing.
In December last year, Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.
Shares of Natco Pharma were today trading at Rs 949.55 per scrip on BSE, down 4.73 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
